US equities |
NVDA $234.84 ▲+1.72% MU $1,080.60 ▼-1.53% TSLA $371.93 ▲+5.03% SPCX $157.70 ▲+6.50% SNDK $1,723.10 ▼-3.61% AMD $630.26 ▲+2.36% STX $834.26 ▼-11.77% WDC $411.10 ▼-11.13%
FinancialContent

Pacira BioSciences, Inc. - Common Stock (NQ:PCRX)

25.14 +0.13 (+0.52%)
Delayed Quote Updated: 1:14 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Pacira BioSciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira BioSciences Announces Publication of Positive Two-Year Phase 1 Data For PCRX-201 in Annals of the Rheumatic Diseases
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira BioSciences Reports Second Quarter 2026 Financial Results
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira BioSciences Announces New National Survey Revealing the Hidden Toll of Pain on America’s Workforce
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira BioSciences Advances PCRX-201 Development Program with Successful Transition to Scalable Commercial Manufacturing Process
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira to Report Second Quarter 2026 Financial Results on Tuesday August 4, 2026
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira BioSciences Announces UnitedHealthcare Now Provides Separate Reimbursement for EXPAREL®
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira BioSciences Announces Agreement to Divest its iovera° Business to Zimmer Biomet
From Pacira BioSciences
Via GlobeNewswire
News headline image
Leading Independent Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote “FOR” All of Pacira’s Director Nominees
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira BioSciences Mails Letter to Stockholders Reiterating Confidence in the Company’s Strategic Direction and Highly Qualified Nominees
From Pacira BioSciences
Via GlobeNewswire
News headline image
After Fifty Years of Implants, a Newly Public Biotech Is Trying to Rebuild the Breast Instead
Issued on behalf of Conexeu Sciences Inc. 
From Biotech Insider
Via GlobeNewswire
News headline image
Pacira BioSciences Reports Real-World Study Showing EXPAREL® Use Was Associated with Reduced Opioid Use and Healthcare Costs in Patients Undergoing Total Shoulder Arthroplasty
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira BioSciences Sets the Record Straight Regarding DOMA’s Misleading Statements About Pacira’s Intellectual Property Strategy
From Pacira BioSciences
Via GlobeNewswire
News headline image
A Reno Biotech Just Rang the Nasdaq Bell — Here’s Why the Whole Regenerative-Medicine Tape Is Worth Watching
Issued on behalf of Conexeu Sciences Inc. 
From World Street Intelligence
Via GlobeNewswire
News headline image
Pacira BioSciences Files Investor Presentation Highlighting Successful Execution of its Long-Term Strategy to Drive Value for All Stockholders
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira BioSciences to Participate in Fireside Chats at Three Upcoming Healthcare Conferences
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira BioSciences Sends Letter to Stockholders Reiterating Superior Qualifications of its Board Nominees
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira BioSciences Mails Letter to Stockholders
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira BioSciences Reports First Quarter 2026 Financial Results
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira BioSciences Files Definitive Proxy Materials and Mails Letter to Shareholders
From Pacira BioSciences
Via GlobeNewswire
News headline image
Real-World Data on EXPAREL® Shows Reduced Opioid Use and Lower Total Medical Costs in Medicare Patients Undergoing Total Hip Arthroplasty
-- Findings show significant reductions in opioid consumption, healthcare resource utilization, and total medical costs -- 
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira to Report First Quarter 2026 Financial Results on Thursday April 30, 2026
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira Presents Real-World Data on EXPAREL® Showing Lower Total Healthcare Costs in Outpatient Total Hip and Knee Arthroplasty Procedures
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira BioSciences to Present Real-World Data on EXPAREL® Showing Reduced Cost of Care at Orthopaedic Research Society 2026 Annual Meeting
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira BioSciences Reaffirms Commitment to Shareholder Value Creation
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira BioSciences to Participate in Fireside Chat at the Barclays 28th Annual Global Healthcare Conference
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira BioSciences Presents Two Real-World Studies from Its Innovations in Genicular Outcomes Registry (IGOR)
From Pacira BioSciences
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >